Arkolith/Insider Trading/XERS/Form 4

Shannon John Patrick Jr

See Remarks, DirectorXeris Biopharma Holdings, Inc. (XERS) · full profile →Form 4 · filed Jan 6, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$176K
Net Open-Market Flow
-$176K
Transactions
7
4 non-derivative · 3 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 5, 2026Sell(S)25K$7.08$176K2.7M
Jan 5, 2026Option exercise(M)3K$3.94$11K2.8M
Jan 5, 2026Option exercise(M)25K$1.55$39K2.8M
Jan 5, 2026Option exercise(M)64K$1.55$100K2.8M

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 5, 2026Option exercise(M)25K—$00
Jan 5, 2026Option exercise(M)3K—$097K
Jan 5, 2026Option exercise(M)64K—$00

Transaction Codes

S
Open-market sale
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001553595-26-000002) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML